Valitor employs its proprietary Multivalent Polymer (MVP) platform to conjugate multiple copies of anti‑VEGF proteins onto a custom biopolymer scaffold, creating a long‑acting ocular biologic. The lead candidate, VLTR‑559, achieves six‑month therapeutic exposure after a single intravitreal injection while maintaining potency comparable to current short‑acting agents. The modular MVP system enables rapid development of additional ophthalmic and non‑ocular macromolecular therapeutics.
Funding
$28M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MFounders
Product
Problem
Current anti‑VEGF treatments for wet age‑related macular degeneration require intravitreal injections every 8–12 weeks, creating a high clinical burden and limiting long‑term adherence. Conventional biologics also exhibit rapid ocular clearance, short half‑life, and susceptibility to deactivation, which restricts therapeutic durability and efficacy.
Solution
Valitor leverages its proprietary Multivalent Polymer (MVP) platform to conjugate multiple copies of a bioactive molecule onto a custom‑designed biopolymer scaffold. This architecture independently tunes pharmacokinetic and pharmacodynamic attributes, delivering extended ocular residence time, enhanced target engagement, and improved stability. Using the MVP platform, Valitor has engineered VLTR‑559, a long‑acting anti‑VEGF biologic designed to maintain therapeutic levels for six months or longer after a single intravitreal injection. Preclinical studies demonstrate that VLTR‑559 retains potency comparable to approved short‑acting agents while achieving three‑ to four‑fold longer tissue half‑life and a safety profile consistent with existing therapies. The platform is interchangeable, allowing rapid assembly of additional ophthalmic candidates and potential expansion into other therapeutic areas.
Target Audience
Primary customers are retina specialists and ophthalmology clinics treating wet AMD, as well as pharmaceutical partners seeking a platform for long‑acting ocular biologics.
Features
- Multivalent Polymer (MVP) scaffold that can be loaded with multiple copies of a protein therapeutic, enabling independent control of PK/PD parameters.
- Engineered for extended target tissue retention, providing ocular half‑life up to 4× longer than first‑generation anti‑VEGF agents.
- Protective polymer matrix reduces enzymatic deactivation, enhancing pharmacostability in the vitreous environment.
- High potency achieved through multivalent binding, delivering ≥3‑fold increased efficacy in preclinical wet‑AMD models.
- Modular biopolymer‑bioactive coupling permits rapid generation of new macromolecular therapeutics for ophthalmology and other indications (e.g., oncology, musculoskeletal).
- Scalable CMC process with demonstrated manufacturability and IND‑enabling data for VLTR‑559.
- Integrated safety assessment showing tolerability comparable to approved short‑acting anti‑VEGF drugs.